Gelteq Announces 400,000 Units Enter into Production in November 2024
Gelteq (NASDAQ: GELS) announces the production of 400,000 units of its gel solution in November 2024. The production run includes nutraceutical products for sports, anti-aging, and weight loss, fulfilling orders for clients in the U.S. and Australia. Delivery is expected in January 2025, with sales extending to the UAE and Asia. The company states this production milestone follows their recent IPO and demonstrates their ability to execute large-scale sales while maintaining research and development activities. Gelteq also highlights their strengthened partnership with Monash Innovation Labs to ensure quality and scalability.
Gelteq (NASDAQ: GELS) annuncia la produzione di 400.000 unità della sua soluzione gel nel novembre 2024. Il ciclo di produzione include prodotti nutraceutici per lo sport, l'antinvecchiamento e la perdita di peso, soddisfacendo gli ordini dei clienti negli Stati Uniti e in Australia. La consegna è prevista per gennaio 2025, con vendite che si estendono agli Emirati Arabi Uniti e all'Asia. L'azienda afferma che questo traguardo produttivo segue il loro recente IPO e dimostra la loro capacità di eseguire vendite su larga scala mantenendo al contempo attività di ricerca e sviluppo. Gelteq sottolinea anche il rafforzamento della loro partnership con i Monash Innovation Labs per garantire qualità e scalabilità.
Gelteq (NASDAQ: GELS) anuncia la producción de 400,000 unidades de su solución en gel en noviembre de 2024. La producción incluye productos nutracéuticos para el deporte, el antienvejecimiento y la pérdida de peso, cumpliendo con los pedidos de clientes en EE. UU. y Australia. Se espera que la entrega ocurra en enero de 2025, con ventas que se extenderán a los EAU y Asia. La empresa afirma que este hito productivo sigue a su reciente IPO y demuestra su capacidad para llevar a cabo ventas a gran escala mientras mantiene actividades de investigación y desarrollo. Gelteq también destaca su fortalecida asociación con Monash Innovation Labs para garantizar calidad y escalabilidad.
겔텍 (NASDAQ: GELS)은 2024년 11월에 40만 개의 젤 솔루션을 생산한다고 발표했습니다. 이 생산은 스포츠, 노화 방지 및 체중 감소를 위한 영양소 제품을 포함하며, 미국과 호주 고객의 주문을 충족합니다. 배달은 2025년 1월로 예정되어 있으며, 판매는 UAE와 아시아로 확대될 것입니다. 이 회사는 이번 생산 이정표가 최근 IPO에 따른 것이며, 연구 및 개발 활동을 유지하면서 대규모 판매를 실행할 수 있는 능력을 보여준다고 밝혔습니다. 겔텍은 또한 품질과 확장성을 보장하기 위해 모나시 혁신 연구소와의 파트너십 강화도 강조했습니다.
Gelteq (NASDAQ: GELS) annonce la production de 400 000 unités de sa solution en gel en novembre 2024. La série de production comprend des produits nutraceutiques pour le sport, l'anti-âge et la perte de poids, satisfaisant les commandes des clients aux États-Unis et en Australie. La livraison est prévue pour janvier 2025, avec des ventes qui s'étendront aux EAU et à l'Asie. L'entreprise déclare que cette étape de production fait suite à leur récente introduction en bourse et démontre leur capacité à exécuter des ventes à grande échelle tout en maintenant des activités de recherche et développement. Gelteq souligne également le renforcement de son partenariat avec les Monash Innovation Labs pour garantir la qualité et l'évolutivité.
Gelteq (NASDAQ: GELS) kündigt die Produktion von 400.000 Einheiten seiner Gel-Lösung im November 2024 an. Die Produktionsreihe umfasst nutraceutical Produkte für Sport, Anti-Aging und Gewichtsverlust und erfüllt Bestellungen von Kunden in den USA und Australien. Die Lieferung wird für Januar 2025 erwartet, während die Verkäufe sich auf die VAE und Asien ausdehnen. Das Unternehmen erklärt, dass dieser Produktionsmeilenstein auf ihren jüngsten Börsengang folgt und ihre Fähigkeit unter Beweis stellt, große Verkaufszahlen zu realisieren, während Forschungs- und Entwicklungsaktivitäten aufrechterhalten werden. Gelteq hebt auch die verstärkte Partnerschaft mit Monash Innovation Labs hervor, um Qualität und Skalierbarkeit sicherzustellen.
- Secured orders for 400,000 units of gel solution products
- Geographic expansion with sales across multiple regions (US, Australia, UAE, Asia)
- Production commenced shortly after IPO, indicating strong market demand
- Partnership with Monash Innovation Labs enables scalable production
- Revenue generation still pending as delivery expected in January 2025
Insights
This production milestone of 400,000 units represents Gelteq's first major commercial rollout following their IPO. The multi-country distribution across the U.S., Australia, UAE and Asia demonstrates promising market penetration for their gel-based delivery technology. The focus on high-growth segments like sports nutrition, anti-aging and weight loss positions them well in the nutraceutical market.
The partnership with Monash Innovation Labs provides important manufacturing scalability, though investors should note that revenue impact won't materialize until January 2025. For a micro-cap company with a
NEW YORK, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Gelteq Limited (NASDAQ: GELS) (“Gelteq” or the “Company”), a clinical and science-based company focused on developing and commercializing white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care, and other products, announces today that in November, 400,000 units of its gel solution are entering into production. These units will fulfill orders made for clients in the U.S and Australia. Delivery is expected in January 2025 for sales across the two countries as well as in the UAE and in Asia. The production run includes Gelteq nutraceutical products in the areas of sports, anti-aging, and weight loss.
Gelteq Co-Founder and CEO Nathan Givoni stated, “Our recent IPO was undertaken to provide the necessary capital and awareness of our technology to commence larger scale sales, whilst balancing our research and development activities. To see such volumes entering production so soon after the IPO is a testament to our team executing our plans, together with market validation on our gel-based technology. This production run demonstrates our ability to sell our products to end-users across the world and our ability to begin deriving revenues in the near term.”
Gelteq Co-Founder and Executive Chairman Simon Szewach stated, “Earlier this year, we strengthened our partnership with Monash Innovation Labs, which allows us to effectively scale and meet our client needs, while ensuring the quality of products. The orders connected to this production run are substantial and we believe that they represent the start of even larger volume orders to come.”
About Gelteq Inc.
Headquartered in Melbourne, Australia, Gelteq (NASDAQ: GELS) is a clinical and science-based company that is focused on developing and commercializing white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care and other products. Gelteq is focused on advancing and commercializing its delivery solutions within five core verticals: pharmaceuticals, over-the-counter medications, nutraceuticals, animal medications, and sports nutrition. Gelteq’s unique formulation directly addresses the issues associated with traditional drug delivery methods such as difficulty swallowing, taste of unpalatable ingredients, and dosage control. For more information, visit www.gelteq.com.
Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “suggest,” “target,” “aim,” “should,” "will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Gelteq’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including risks related to the timing and fulfilment of current and future orders relating to Gelteq’s products, the success of new programs, the ability to implement a new strategic plan and the success of a new strategic plan. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Gelteq in general, see the risk factors in its annual report for the year ended June 30, 2024. All such forward-looking statements speak only as of the date they are made, and Gelteq undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise.
Contact:
CORE IR
516-222-2560
PR@gelteq.com
FAQ
How many units of gel solution is Gelteq (GELS) producing in November 2024?
When will Gelteq (GELS) deliver the November 2024 production units?
Which markets will Gelteq (GELS) distribute its November 2024 production to?
What types of products are included in Gelteq's (GELS) November 2024 production run?
